Search

Your search keyword '"Canioni D"' showing total 472 results
Start Over Author "Canioni D"
472 results on '"Canioni D"'

3. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial

Author

Petrella, T., Copie-Bergman, C., Brière, J., Delarue, R., Jardin, F., Ruminy, P., Thieblemont, C., Figeac, M., Canioni, D., Feugier, P., Fabiani, B., Leroy, K., Parrens, M., André, M., Haioun, C., Salles, G.A., Gaulard, P., Tilly, H., Jais, J.P., and Molina, T.J.

Published
2017
Full Text
View/download PDF

6. FDG-PET/CT findings in systemic mastocytosis: a French multicentre study

Author

Djelbani-Ahmed, S., Chandesris, M. O., Mekinian, A., Canioni, D., Brouzes, C., Hanssens, K., Pop, G., Durieu, I., Durupt, S., Grosbois, B., Besnard, S., Tournilhac, O., Beyne-Rauzy, O., Agapé, P., Delmer, A., Ranta, D., Jeandel, P. Y., Georgin-Lavialle, S., Frenzel, L., Damaj, G., Eder, V., Lortholary, O., Hermine, O., Fain, O., and Soussan, M.

Published
2015
Full Text
View/download PDF

7. The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis

Author

Polivka, L., primary, Parietti, V., additional, Bruneau, J., additional, Soucie, E., additional, Madrange, M., additional, Bayard, E., additional, Rignault, R., additional, Canioni, D., additional, Fraitag, S., additional, Lhermitte, L., additional, Feroul, M., additional, Tissandier, M., additional, Rossignol, J., additional, Frenzel, L., additional, Cagnard, N., additional, Meni, C., additional, Bouktit, H., additional, Collange, A.-F., additional, Gougoula, C., additional, Parisot, M., additional, Bader-Meunier, B., additional, Livideanu, C., additional, Laurent, C., additional, Arock, M., additional, Hadj-Rabia, S., additional, Rüther, U., additional, Dubreuil, P., additional, Bodemer, C., additional, Hermine, O., additional, and Maouche-Chrétien, L., additional

Published
2021
Full Text
View/download PDF

11. HIGH‐RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDY

Author

Cheminant, M., primary, Burroni, B., additional, Bris, Y., additional, Chartier, L., additional, Oberic, L., additional, Ribrag, V., additional, Delfau, M.‐H., additional, Thieblemont, C., additional, Gressin, R., additional, Canioni, D., additional, Peyre, M., additional, Laurent, C., additional, Steimle, T., additional, Kaltenbach, S., additional, Asnafi, V., additional, Macintyre, E., additional, Callanan, M., additional, Gouill, S., additional, and Hermine, O., additional

Published
2021
Full Text
View/download PDF

13. Long-term outcome, growth and digestive function in children 2 to 18 years after intestinal transplantation

Author

Lacaille, F., Vass, N., Sauvat, F., Canioni, D., Colomb, V., Talbotec, C., Patey-Mariaud De Serre, N., Salomon, J., Hugot, J.-P., Cezard, J.-P., Revillon, Y., Ruemme, F.M., and Goulet, O.

Subjects
Transplantation of organs, tissues, etc. -- Patient outcomes, Transplantation of organs, tissues, etc. -- Demographic aspects, Parenteral feeding -- Physiological aspects, Parenteral feeding -- Research, Parenteral therapy -- Physiological aspects, Parenteral therapy -- Research, Health
Published
2008

14. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936

Author

Evans, P A S, Pott, Ch, Groenen, P J T A, Salles, G, Davi, F, Berger, F, Garcia, J F, van Krieken, J H J M, Pals, S, Kluin, Ph, Schuuring, E, Spaargaren, M, Boone, E, González, D, Martinez, B, Villuendas, R, Gameiro, P, Diss, T C, Mills, K, Morgan, G J, Carter, G I, Milner, B J, Pearson, D, Hummel, M, Jung, W, Ott, M, Canioni, D, Beldjord, K, Bastard, C, Delfau-Larue, M H, van Dongen, J J M, Molina, T J, and Cabeçadas, J

Published
2007
Full Text
View/download PDF

16. Implication de la voie de signalisation Hedgehog dans les mastocytoses

Author

Polivka, L., primary, Parietti, V., additional, Soucie, E., additional, Bayard, E., additional, Canioni, D., additional, Fraitag, S., additional, Lhermitte, L., additional, Tissandier, M., additional, Rossignol, J., additional, Cagnard, N., additional, Bader-Meunier, B., additional, Arock, M., additional, Hadj-Rabia, S., additional, Dubreuil, P., additional, Bodemer, C., additional, Hermine, O., additional, and Maouche-Chrétien, L., additional

Published
2020
Full Text
View/download PDF

27. PS1251 CLINICO‐BIOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR BLASTOID MANTLE CELL LYMPHOMA PATIENTS INCLUDED IN CLINICAL TRIALS. A LYSA STUDY

Author

Baldacini, M., primary, Burroni, B., additional, Le Gouill, S., additional, Gressin, R., additional, Hermine, O., additional, Traverse‐glehen, A., additional, Martin, A., additional, Moreau, A., additional, Bene, M.C., additional, Fogarty, P., additional, Canioni, D., additional, and Fornecker, L.‐M., additional

Published
2019
Full Text
View/download PDF

28. OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY

Author

Le Gouill, S., primary, Beldi‐Ferchiou, A., additional, Cacheux, V., additional, Salles, G., additional, Canioni, D., additional, Bodet‐Milin, C., additional, Alcantara, M., additional, Delwail, V., additional, Gastinne, T., additional, Thieblemont, C., additional, Maisonneuve, H., additional, Lamy de la Chapelle, T., additional, Oberic, l., additional, Bouabdallah, K., additional, Ribrag, V., additional, Delfau‐Larue, M., additional, Macintyre, E., additional, and Hermine, O., additional

Published
2019
Full Text
View/download PDF

29. S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL

Author

Legouill, S., primary, Beldi-Ferchiou, A., additional, Cacheux, V., additional, Alcantara, M., additional, Salles, G., additional, Canioni, D., additional, Bodet-Milin, C., additional, Delwail, V., additional, Gastinne, T., additional, thieblemont, C., additional, Moles, M.-P., additional, Damaj, G., additional, Jaccard, A., additional, Daguindau, N., additional, Ribrag, V., additional, Delfau-Larue, M.-H., additional, Macintyre, E., additional, and Hermine, O., additional

Published
2019
Full Text
View/download PDF

30. CLINICO-BIOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR AGRESSIVE MANTLE CELL LYMPHOMA PATIENTS INCLUDED IN CLINICAL TRIALS. A LYSA STUDY

Author

Baldacini, M., primary, Burroni, B., additional, Le Gouill, S., additional, Gressin, R., additional, Hermine, O., additional, Traverse-glehen, A., additional, Martin, A., additional, Moreau, A., additional, Bene, M., additional, Fogarty, P., additional, Canioni, D., additional, and Fornecker, L., additional

Published
2019
Full Text
View/download PDF

31. REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE

Author

Bossard, C., primary, Laghmari, O., additional, Le Bris, Y., additional, Bonnet, A., additional, Moreau, A., additional, El Alami Thomas, W., additional, Pavageau, A., additional, Guerzider, P., additional, Maisonneuve, H., additional, Ruminy, P., additional, Bene, M., additional, Casasnovas, O., additional, Canioni, D., additional, Thieblemont, C., additional, Petrella, T., additional, Jardin, F., additional, Salles, G., additional, Tilly, H., additional, Gaulard, P., additional, Haioun, C., additional, Brière, J., additional, Le Gouill, S., additional, Copie Bergman, C., additional, and Molina, T.J., additional

Published
2019
Full Text
View/download PDF

35. Accuracy in Diagnosis of Celiac Disease Without Biopsies in Clinical Practice

Author

Werkstetter, K.J. Korponay-Szabó, I.R. Popp, A. Villanacci, V. Salemme, M. Heilig, G. Lillevang, S.T. Mearin, M.L. Ribes-Koninckx, C. Thomas, A. Troncone, R. Filipiak, B. Mäki, M. Gyimesi, J. Najafi, M. Dolinšek, J. Dydensborg Sander, S. Auricchio, R. Papadopoulou, A. Vécsei, A. Szitanyi, P. Donat, E. Nenna, R. Alliet, P. Penagini, F. Garnier-Lengliné, H. Castillejo, G. Kurppa, K. Shamir, R. Hauer, A.C. Smets, F. Corujeira, S. van Winckel, M. Buderus, S. Chong, S. Husby, S. Koletzko, S. Socha, P. Cukrowska, B. Szajewska, H. Wyhowski, J. Brown, N. Batra, G. Misak, Z. Seiwerth, S. Dmitrieva, Y. Abramov, D. Vandenplas, Y. Goossens, A. Schaart, M.W. Smit, V.T.H.B.M. Kalach, N. Gosset, P. Kovács, J.B. Nagy, A. Lellei, I. Kőbányai, R. Khatami, K. Monajemzadeh, M. Dimakou, K. Patereli, A. Hansen, T.P. Kavalar, R. Bolonio, M. Ramos, D. Kogler, H. Amann, G. Kosova, R. Maglio, M. Janssens, E. Achten, R. Frűhauf, P. Skálová, H. Kirchner, T. Petrarca, L. Magliocca, F.M. Martínez, F. Morente, V. Thanner-Lechner, S. Ratschek, M. Gasparetto, M. Hook, L. Canioni, D. Wanty, C. Mourin, A. Laurila, K. Vornane, M. Friedler, V.N. Morgenstern, S.L. Amil Dias, J. Carneiro, F. João, H.S. Van Biervliet, S. Velde, S.V. Banoub, H. Sampson, S. Müller, A.M. Ene, A. Rafeey, M. Eftekhar Sadat, A.T. ProCeDE study group ProCeDE study group

Abstract

Background & Aims The guidelines of the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition allow for diagnosis of celiac disease without biopsies in children with symptoms and levels of immunoglobulin A against tissue-transglutaminase (TGA-IgA) 10-fold or more the upper limit of normal (ULN), confirmed by detection of endomysium antibodies (EMA) and positivity for HLA-DQ2/DQ8. We performed a large, international prospective study to validate this approach. Methods We collected data from consecutive pediatric patients (18 years or younger) on a gluten-containing diet who tested positive for TGA-IgA from November 2011 through May 2014, seen at 33 pediatric gastroenterology units in 21 countries. Local centers recorded symptoms; measurements of total IgA, TGA, and EMA; and histopathology findings from duodenal biopsies. Children were considered to have malabsorption if they had chronic diarrhea, weight loss (or insufficient gain), growth failure, or anemia. We directly compared central findings from 16 antibody tests (8 for TGA-IgA, 1 for TGA-IgG, 6 for IgG against deamidated gliadin peptides, and 1 for EMA, from 5 different manufacturers), 2 HLA-DQ2/DQ8 tests from 2 manufacturers, and histopathology findings from the reference pathologist. Final diagnoses were based on local and central results. If all local and central results were concordant for celiac disease, cases were classified as proven celiac disease. Patients with only a low level of TGA-IgA (threefold or less the ULN) but no other results indicating celiac disease were classified as no celiac disease. Central histo-morphometry analyses were performed on all other biopsies and cases were carefully reviewed in a blinded manner. Inconclusive cases were regarded as not having celiac disease for calculation of diagnostic accuracy. The primary aim was to determine whether the nonbiopsy approach identifies children with celiac disease with a positive predictive value (PPV) above 99% in clinical practice. Secondary aims included comparing performance of different serological tests and to determine whether the suggested criteria can be simplified. Results Of 803 children recruited for the study, 96 were excluded due to incomplete data, low level of IgA, or poor-quality biopsies. In the remaining 707 children (65.1% girls; median age, 6.2 years), 645 were diagnosed with celiac disease, 46 were found not to have celiac disease, and 16 had inconclusive results. Findings from local laboratories of TGA-IgA 10-fold or more the ULN, a positive result from the test for EMA, and any symptom identified children with celiac disease (n = 399) with a PPV of 99.75 (95% confidence interval [CI], 98.61–99.99); the PPV was 100.00 (95% CI, 98.68–100.00) when only malabsorption symptoms were used instead of any symptom (n = 278). Inclusion of HLA analyses did not increase accuracy. Findings from central laboratories differed greatly for patients with lower levels of antibodies, but when levels of TGA-IgA were 10-fold or more the ULN, PPVs ranged from 99.63 (95% CI, 98.67–99.96) to 100.00 (95% CI, 99.23–100.00). Conclusions Children can be accurately diagnosed with celiac disease without biopsy analysis. Diagnosis based on level of TGA-IgA 10-fold or more the ULN, a positive result from the EMA tests in a second blood sample, and the presence of at least 1 symptom could avoid risks and costs of endoscopy for more than half the children with celiac disease worldwide. HLA analysis is not required for accurate diagnosis. Clinical Trial Registration no: DRKS00003555. © 2017 AGA Institute

Published
2017

39. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, Petrella, T, Copie-Bergman, C, Brière, J, Delarue, R, Jardin, F, Ruminy, P, Thieblemont, C, Figeac, M, Canioni, D, Feugier, P, Fabiani, B, Leroy, K, Parrens, M, André, Marc, Haioun, C, Salles, G A, Gaulard, P, Tilly, H, Jais, J P, Molina, T J, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, Petrella, T, Copie-Bergman, C, Brière, J, Delarue, R, Jardin, F, Ruminy, P, Thieblemont, C, Figeac, M, Canioni, D, Feugier, P, Fabiani, B, Leroy, K, Parrens, M, André, Marc, Haioun, C, Salles, G A, Gaulard, P, Tilly, H, Jais, J P, and Molina, T J

Abstract

BACKGROUND: Our aim was to evaluate whether the cell of origin (COO) as defined by the Hans algorithm and MYC/BCL2 coexpression, which are the two main biological risk factors in elderly patients treated with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP), maintain their prognostic value in a large prospective clinical trial. PATIENTS AND METHODS: We evaluated 285 paraffin-embedded samples from patients (60-80 years of age) enrolled in the Lymphoma Study Association trial LNH03-6B who were treated with R-CHOP. We correlated the COO defined by the transcriptome according to the Wright algorithm with that defined by the Hans algorithm in a subset of 62 tumors with available frozen tissue samples. RESULTS: The non-germinal center B-cell-like phenotype according to the Hans algorithm and BCL2 expression (but not MYC and BCL2 coexpression) predicted worse progression-free survival [hazard ratio (HR)=1.78, P = 0.003 and HR = 1.79, P = 0.003, respectively] and overall survival (HR = 1.85, P = 0.005 and HR = 1.67, P = 0.02, respectively) independently of the International Prognostic Index. The correlation between the Hans algorithm and the Wright algorithm was 91%, with an almost perfect concordance according to a kappa test (0.81). CONCLUSIONS: Our results suggest that immunohistochemically defined COO remains a useful tool for predicting prognosis in diffuse large B-cell lymphoma when performed under optimized standardized conditions and that BCL2 expression may help to identify elderly patients at risk for relapse and who could potentially respond to anti-BCL2 targeted agents. In this prospective phase III trial, the coexpression of MYC and BCL2 does not appear to predict worse survival. CLINICAL TRIAL NUMBER: NCT00144755.

Published
2017

40. PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN STAGE III/IV CLASSICAL HODGKIN LYMPHOMA TREATED FRONTLINE IN THE LYSA EORTC 20012 RANDOMIZED PROTOCOL

Author

Canioni, D., primary, Brice, P., additional, Bologna, S., additional, Voillat, L., additional, Gabarre, J., additional, Casasnovas, O., additional, Devidas, A., additional, Coiffier, B., additional, Aoudjhane, A., additional, Audouy, B., additional, Andre, M., additional, Fortpied, C., additional, Carde, P., additional, Mounier, N., additional, and Briere, J., additional

Published
2017
Full Text
View/download PDF

41. Masitinib dans le traitement de la mastocytose systemique sévère de forme indolente ou latente : un essai clinique de phase 3 randomisé et controllé

Author

Lortholary, O., primary, Chandesris, M.-O., additional, Bulai Livideanu, C., additional, Paul, C., additional, Guillet, G., additional, Jassem, E., additional, Niedoszytko, M., additional, Barete, S., additional, Verstovsek, S., additional, Damaj, G., additional, Canioni, D., additional, Fraitag, S., additional, Lhermitte, L., additional, Georgin-Lavialle, S., additional, Afrin, L., additional, Hanssens, K., additional, Agopian, J., additional, Kinet, J.-P., additional, Auclair, C., additional, Mansfield, C., additional, Moussy, A., additional, Dubreuil, P., additional, and Hermine, O., additional

Published
2016
Full Text
View/download PDF

43. CD30 expression in cutaneous lesions of systemic mastocytosis: clinical, biological and histopathological analysis of 27 patients.

Author

Poirier, E., Fraitag, S., Tezenas du Montcel, S., Moguelet, P., Charlotte, F., Lortholary, O., Hermine, O., Canioni, D., and Barete, S.

Subjects
MAST cell disease, MAST cells
Abstract

The affected BSA values and median serum tryptase levels were higher for CD30 SP + sp patients but were not statistically different from those of CD30 SP - sp patients. The number of CB MCs per HPF for CD30 SP + sp patients was higher than that for CD30 SP - sp patients. Characteristics of systemic mastocytosis patients with CD30 positivity or negativity in cutaneous and bone marrow biopsies. [Extracted from the article]

Published
2019
Full Text
View/download PDF

44. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

Author

Lamarque, M., primary, Bossard, C., additional, Contejean, A., additional, Brice, P., additional, Parrens, M., additional, Gouill, S. L., additional, Briere, J., additional, Bouabdallah, R., additional, Canioni, D., additional, Tilly, H., additional, Bouchindhomme, B., additional, Bachy, E., additional, Delarue, R., additional, Haioun, C., additional, and Gaulard, P., additional

Published
2015
Full Text
View/download PDF

45. Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms

Author

Georgin-Lavialle, S., primary, Launay, J.-M., additional, Côté, F., additional, Soucié, E., additional, Soria, A., additional, Damaj, G., additional, Moura, D. S., additional, Canioni, D., additional, Hanssens, K., additional, Chandesris, M.-O., additional, Barète, S., additional, Dubreuil, P., additional, Lortholary, O., additional, Hermine, O., additional, and Sokol, H., additional

Published
2015
Full Text
View/download PDF

48. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to Masitinib, a c-kit tyrosine kinase inhibitor

Author

Georgin-Lavialle, S., Lhermitte, L., Suarez, F., Yang, Y., Letard, S., Hanssens, K., Feger, F., Renand, A., Brouze, C., Canioni, D., Asnafi, V., M.O., Chandesris, Aouba, A., Gineste, P., Macintyre, E., Cd, Mansfield, Moussy, A., Lepelletier, Y., Dubreuil, Pascal, Hermine, O., Slama, Catherine, Cytokines, hématopoïèse et réponse immune (CHRI), Université Paris Descartes - Paris 5 (UPD5) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Centre National de la Recherche Scientifique (CNRS), and Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2012

50. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets

Author

de Leval, L., primary, Parrens, M., additional, Le Bras, F., additional, Jais, J.-P., additional, Fataccioli, V., additional, Martin, A., additional, Lamant, L., additional, Delarue, R., additional, Berger, F., additional, Arbion, F., additional, Bossard, C., additional, Copin, M.-C., additional, Canioni, D., additional, Charlotte, F., additional, Damaj, G., additional, Dartigues, P., additional, Fabiani, B., additional, Ledoux-Pilon, A., additional, Montagne, K., additional, Molina, T., additional, Patey, M., additional, Tas, P., additional, Peoch, M., additional, Petit, B., additional, Petrella, T., additional, Picquenot, J.-M., additional, Rousset, T., additional, Rousselet, M.-C., additional, Soubeyran, I., additional, Thiebault, S., additional, Tournilhac, O., additional, Xerri, L., additional, Gisselbrecht, C., additional, Haioun, C., additional, Delsol, G., additional, and Gaulard, P., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results